News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
197,877 Results
Type
Article (12957)
Company Profile (70)
Press Release (184850)
Section
Business (51161)
Career Advice (906)
Deals (8039)
Drug Delivery (15)
Drug Development (47932)
Employer Resources (59)
FDA (4806)
Job Trends (5056)
News (108441)
Policy (8153)
Tag
Academia (1103)
Allergies (46)
Alliances (16268)
Alzheimer's disease (607)
Approvals (4791)
Artificial intelligence (51)
Best Places to Work (4682)
Biotechnology (58)
Breast cancer (107)
Cancer (853)
Career advice (757)
CAR-T (62)
Cell therapy (162)
Clinical research (39273)
Collaboration (192)
COVID-19 (1651)
Cystic fibrosis (49)
Data (872)
Diabetes (66)
Diagnostics (1643)
Earnings (18221)
Employer resources (51)
Events (29590)
Executive appointments (115)
FDA (5064)
Funding (155)
Gene therapy (88)
GLP-1 (202)
Government (1518)
Healthcare (7042)
Immunology and inflammation (47)
Infectious disease (1705)
Inflammatory bowel disease (62)
Interviews (138)
IPO (3825)
Job creations (609)
Job search strategy (698)
Layoffs (102)
Legal (807)
Lung cancer (126)
Lymphoma (67)
Manufacturing (58)
Medical device (1828)
Medtech (1830)
Mergers & acquisitions (4329)
Metabolic disorders (172)
Neuroscience (785)
NextGen Class of 2024 (2162)
Non-profit (1734)
Northern California (730)
Obesity (95)
Opinion (59)
Parkinson's disease (52)
Peanut (39)
People (13124)
Phase I (14509)
Phase II (17956)
Phase III (10983)
Pipeline (285)
Postmarket research (930)
Preclinical (4100)
Radiopharmaceuticals (95)
Rare diseases (115)
Real estate (1312)
Regulatory (6404)
Research institute (1211)
Resumes & cover letters (137)
Southern California (584)
Startups (1102)
United States (5841)
Vaccines (457)
Weight loss (59)
Date
Last 7 days (371)
Last 30 days (1067)
Last 365 days (14416)
2024 (14092)
2023 (16103)
2022 (19621)
2021 (20549)
2020 (19237)
2019 (15584)
2018 (11855)
2017 (10406)
2016 (9118)
2015 (10427)
2014 (6922)
2013 (5305)
2012 (5539)
2011 (5848)
2010 (4836)
Location
Africa (250)
Asia (13790)
Australia (2351)
California (1551)
Canada (513)
China (149)
Colorado (68)
Connecticut (55)
Delaware (51)
Europe (29878)
Florida (215)
Georgia (43)
Illinois (118)
Indiana (93)
Maryland (229)
Massachusetts (1197)
Michigan (40)
Minnesota (44)
New Jersey (466)
New York (486)
North Carolina (228)
Northern California (730)
Ohio (46)
Pennsylvania (339)
South America (369)
Southern California (584)
Texas (222)
Washington State (215)
197,877 Results for "immune tolerance network".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
October 16, 2024
·
6 min read
Press Releases
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
November 14, 2024
·
11 min read
Biotech Bay
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Repertoire® Immune Medicines announced that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases.
April 29, 2024
·
3 min read
Press Releases
Densitas / ACR Learning Network Strategic Collaboration to Improve Mammography Positioning
November 26, 2024
·
3 min read
Drug Development
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab in patients with persistent or chronic primary immune thrombocytopenia, a rare immune-mediated bleeding disorder.
June 22, 2024
·
11 min read
Career Advice
Career Coach: How to Boost Your Job Application by Networking
Plus, communication errors that cost job offers and how to craft a LinkedIn “About” section
November 14, 2024
·
6 min read
·
Carina Clingman
Immunology & inflammation
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.
December 3, 2024
·
1 min read
·
Heather McKenzie
Press Releases
The US Oncology Network Launches Innovative Program to Foster Retention of New Oncology Nurses
November 21, 2024
·
5 min read
BioMidwest
Genialis and Pancreatic Cancer Action Network (PanCAN) Partner to Progress KRAS Diagnostics
Genialis, the RNA-biomarker company, announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.
May 31, 2024
·
4 min read
Drug Development
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV CureStudy will enroll participants who initiated treatment shortly after acquiring HIV
ACTG today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes therapeutic T-cell vaccines, two broadly neutralizing antibodies (bNAbs), and an immune-system boosting treatment among people living with HIV who started antiretroviral treatment (ART) during acute (early) HIV infection.
April 19, 2024
·
4 min read
1 of 19,788
Next
